Endoscopic submucosal dissection for rectal neoplastic lesions: experience from a European center.

Type
Research paper

Keywords
endoscopic submucosal dissection, rectal tumor, rectal neoplasia

Abstract
Introduction
Nowadays, various endoscopic resections including polypectomy, endoscopic mucosal resection (EMR), and endoscopic submucosal dissection (ESD) are well known first-line approaches for early neoplastic rectal tumors.

Material and methods
In this case series study, we analyzed 320 ESD procedures performed in a high-volume colorectal center in Poland, Europe. The aim of this study was to retrospectively evaluate ESD procedure in cases of rectal carcinoma performed by a single trained operator in a referral center provided with endoscopy.

Results
Overall, en bloc resection was observed in 92.5% of patients (296/320). The en bloc resection rate was at a similar level in those lesions with involved anal sphincters versus tumors without involvement (93.85% vs. 92.16%; p=0.644). R0 resection was noted in 89.4% of patients (286/320). The overall curative ESD rate was 85.94% (n=275). The curative ESD rate in the invasive cancer group reached 52.6% (n=20). We observed ESD-related adverse events, such as bleeding and perforation, in 3.4 % of patients (n=11).

Conclusions
We have demonstrated that ESD in rectal tumors is an efficient and safe procedure with a high curative rate, even in difficult lesions. Anal sphincter localization and recurrent character of the lesion have no impact on the final outcomes. The ESD approach should have been considered for all rectal tumors, especially those lesions suspected of superficial mucosal invasion, as it can serve as a staging method and may have been curative for adenomas and cancers limited to mucosa.
Title: Endoscopic submucosal dissection for rectal neoplastic lesions: experience from a European center.

Short title: The role of ESD in rectal tumors

Authors: Spychalski Michał¹*, Włodarczyk Marcin², Włodarczyk Jakub², Dąbrowski Igor¹, Bednarski Piotr¹, Dziki Adam¹,²

¹Center of Bowel Treatment, Brzeziny, Poland
²Department of General and Colorectal Surgery, Medical University of Lodz, Haller Square 1, 90-624 Lodz, Poland

Statements:
There is no conflict of interest.
There is no grant support or financial relationship.

Corresponding author*:
Spychalski Michał MD, PhD
¹Center of Bowel Treatment, Marii Skłodowskiej-Curie Str. 6, 95-060 Brzeziny, Poland
mail: mpsych80@gmail.com

Word count for the text: 3658 words
Word count for the abstract: 342 words
Abstract:

Introduction:

Nowadays, various endoscopic resections including polypectomy, endoscopic mucosal resection (EMR), and endoscopic submucosal dissection (ESD) are well known first-line approaches for early neoplastic rectal tumors. However, the limited development of colorectal ESD procedures has been observed due to its demanding steep learning curve and higher risk profile in contrast to EMR.

Material and methods:

In this case series study, we analyzed 320 ESD procedures performed by a single operator (MS) after the finishing learning curve in a high-volume endoscopic and colorectal surgery center in Poland, Europe. The aim of this study was to retrospectively evaluate ESD procedure in cases of rectal carcinoma performed by a single trained operator in a tertiary colorectal referral center provided with endoscopy in Poland.

Results:

Overall, en bloc resection was observed in 92.5% of patients (296/320). The en bloc resection rate was at a similar level in those lesions with involved anal sphincters versus tumors without involvement (93.85% vs. 92.16%; p=0.644). R0 resection was noted in 89.4% of patients (286/320). The overall curative ESD rate was 85.94% (n=275). The curative ESD rate in the invasive cancer group reached 52.6% (n=20). We observed ESD-related adverse events, such as bleeding and perforation, in 3.4% of patients (n=11). In multivariate logistic regression, invasive character of lesion and increasing tumor size were associated with a significantly higher odds ratio of the non-curative ESD procedure. Location, recurrence character, and sex had no predictive value.

Conclusions:
We have demonstrated that ESD in rectal tumors is an efficient and safe procedure with a high curative rate, even in difficult lesions. Anal sphincter localization and recurrent character of the lesion have no impact on the final outcomes. The ESD approach should have been considered for all rectal tumors, especially those lesions suspected of superficial mucosal invasion, as it can serve as a staging method and may have been curative for adenomas and cancers limited to mucosa.

Key words:
rectal tumor, endoscopic submucosal dissection, rectal neoplasia
Introduction

Colorectal cancer (CRC) is the third leading cancer in the western world, accounting for approximately 800,000 deaths annually worldwide [1]. Rectal cancer (RC) has been considered and treated as an independent disease due to its primarily extraperitoneal location, potential impairment of anorectal continence and differences in metastatic behavior [2]. The prompt identification and removal of early stage rectal lesions and precancerous lesions are crucial to achieve high quality oncological outcomes [3]. Local resection is particularly desirable in RC patients with low stage of disease, because more extensive surgery may be related with permanent colostomy or anorectal dysfunction, which significantly affects patients’ quality of life (QoL) [4]. Based on current guidelines presented by the European Society of Gastrointestinal Endoscopy (ESGE), the cut-off point for low-risk patients suitable for local resection is well defined as SM1 deep invasion, no vessel invasion and no budding [5]. The local resection techniques not only have a clear benefit on the QoL, but also, associated with lower mortality, morbidity and total costs, in comparison to elective surgery and that is the way they are getting more popular in clinical practice [6,7]. Nowadays, transanal endoscopic microsurgery (TEM), transanal minimally invasive surgery (TAMIS) and various endoscopic resections, such as polypectomy, endoscopic mucosal resection (EMR), and endoscopic submucosal dissection (ESD) are well known first-line approaches for early neoplastic rectal tumors. All techniques are standard of care, but a direct evidence-based conclusion is lacking. The guidelines by the Japan Gastroenterological Endoscopy Society (JGES) and ESGE suggested to consider the ESD procedure in all rectal lesions suspected for superficial submucosal invasion (SMI) or tumors that cannot be resected en bloc in EMR technique [8]. Moreover, the American Gastroenterological Association (AGA) has also recommended ESD for selected rectal tumors, especially those with suspected SMI [9]. The development of ESD in rectal lesions still has been limited due to a higher risk
of adverse events, such as bleeding and perforation, demanding steep learning curve, and
significant differences in training prospects in comparison to Asian endoscopic centers [10–
13]. There is still a lack of data from Western countries covering ESD implementation in the
rectal tumors. Recent studies have shown that ESD may be a safe and efficient approach for
the management of low rectal tumors [14–17]. The aim of the study was to retrospectively
evaluate ESD procedure in cases of rectal carcinoma performed by single trained operator
(who fulfilled the training according to the ESD curriculum developed by the ESGE) in a
tertiary colorectal referral center provided with endoscopy in Poland.

Material and methods

Study population

This single-center, retrospective analysis of a prospectively built database was conducted in
patients who underwent ESD procedure for rectal tumor from 2016 to 2020 at Center of
Bowel Treatment, Brzeziny, Poland by a single operator (MS). Rectal tumors were defined as
any lesion, which upper margin was located within 18cm length from the anal verge and/or
when at least half of the lesion was situated within 15cm from the anal verge. Indication for
ESD procedure included granular-type laterally spreading tumors (LST-Gs) or mixed LST of
≥ 20mm, nongranular-type laterally spreading tumors (LST-NGs) of ≥ 20mm, and tumors
difficult to remove completely with EMR (i.e., lesions after failed EMR, those located near or
at the dentate line, or those with non-lifting sing). Patients with neuroendocrine tumors,
gastrointestinal stromal tumors, and patients with underlying inflammatory bowel disease and
familial adenomatous polyposis were excluded from the study. The data for the study was
collected using a retrospective review of medical documentation.
Endoscopic submucosal dissection procedure

All subjects enrolled to the study, have been admitted to the ward a day before the ESD procedure. Patients have been prepared for procedure with 4-L polyethylene glycol and have received single-dose prophylactic antibiotic therapy. ESD was performed with iv. deep sedation or general anesthesia with endotracheal intubation, at the discretion of the endoscopist and anesthesiologist. Carbon dioxide was used for insufflation in all cases. ESD was performed using the following procedures, as previously described: normal saline with indigocarmine and/or sodium hyaluronate were injected into the submucosal layer around the lesion to raise the mucosal layer [7]. An incision into the mucosa was performed outside the target lesion. The subsequent submucosal dissection of the lesion was performed with a Dual Knife (Olympus Medical Systems, Tokyo, Japan) and/or a Flush Knife-BT (ball tip; Fujifilm, Tokyo, Japan). Traction force during dissection was achieved through gravity. Erbe VIO-300S electrosurgical units (ERBE® Elektromedizin GmbH, Tübingen, Germany) were used (“endo-cut effect 2” for mucosal incision and “swift coagulation mode effect 4/30 W” for submucosal dissection and hemostasis). A Coagrasper (Olympus®) was used for hemostasis whenever necessary (soft coagulation effect 5/80 W). The procedure was performed by single well-trained operator. His learning curve points were analyzed and recently published in peer-reviewed journals [17–20].

Histopathological assessment

All resected specimens were immersed in 10% formalin and sectioned serially at 2mm intervals. All tissue specimens were stained with hematoxylin and eosin. Afterwards, they underwent histopathological evaluation by pathologists in accordance with the Vienna classification and the World Health Organization classification of CRC [21,22].
Histopathological evaluation of resected en bloc lesions involved the assessment of lateral margins of dissection and the depth of SMI.

**Definition of complication and outcome measures**

*En bloc* resection was defined as resection of the rectal tumor in a one single tissue specimen. Complete histologic resection (R0) was defined as an excision of the lesion with negative lateral and deep margins. Incomplete histological resection was defined as failure to achieve neoplasia-negative margins (R1). Curative ESD procedure was defined when all the following criteria were met: (1) resected lesion with negative lateral and deep margins of cancer cells, (2) depth of SMI <1000μm below the muscularis mucosae, (3) absence of poorly differentiated or mucinous histology, (4) absence of lymphovascular involvement and tumor budding, and (5) without severe complication requiring additional surgical treatment. We defined a superficial invasive cancer as a lesion with SMI invasion <1000μm below the muscularis mucosae.

In our study, the post-procedural bleeding has been defined as symptomatic bleeding with loss above 2 g/dl of hemoglobin level after finish of ESD procedure. Other adverse events reported in the study were defined accordingly to recent criteria by the American Society of Gastrointestinal Endoscopy [23].

Primary outcomes of the study were the *En bloc*, R0 and curative rates of the overall analyzed group. The secondary outcomes involved the analysis of *en bloc*, R0 and curative rates in the group of patients with invasive cancer and the complication rates in general group.

**Statistical analysis**

The data gathered in the study were analyzed with the statistical package Statistica 13.1 (StatSoft, Inc., USA). The speed of the procedure (cm2/min) were calculated on assumption that every lesion had a congenial shape to the circle (thus A=pr2 formula was used).
analyzed results were presented as mean ± standard deviation regarding continuous variables and as numbers and percentage referring to categorical variables. Receiver operating characteristic (ROC) curves were constructed, and the areas under the ROC curves with 95% CIs were calculated and compared with each other. The estimation of normality of distribution of the examined quantitative parameters was executed with the W Shapiro-Wilk test. The comparisons of the study groups were performed with the Student's t-test (or nonparametric the Mann-Whitney test, depending on the distribution of variables) and the chi-squared test (or Fischer test). In all the analyses the probability value p<0.05 was considered statistically significant. A multivariate logistic regression was carried out to identify factors related to the curative ESD rate and the following variables as explanatory variables: patient age, sex, tumor diameter, lesion location, recurrence character, presence of neoplasm invasion. Stepwise model selection was used for final variable selection (p-value <0.05 for model entry and p-value >0.1 to exit the model).

**Ethical considerations**

The study was conducted in accordance with the ethical principles of the 1975 Declaration of Helsinki and the study protocol was approved by the Committee of Bioethics of Medical University of Lodz, Poland (RNN/191/20/KE, July 14, 2020).

**Results**

**Patients’ baseline characteristics**

A cohort of 320 successive patients who underwent rectal ESD from January 2016 to December 2020 were enrolled in our study: 171 (53.4%) men and 149 (46.6%) women. The mean resected specimen size was 47.4±27.8mm and located at a mean of 4.5±3.5cm from the anal verge. The most of included cases were presented with tumors located in lower/middle part of rectum. However, the distance from anal verge varied in our study from 0 to 15 cm.
According to the Paris classification 71.7% (n=229) of lesions were categorized as LST-G tumors and 10.3% (n=33) as LST-NG. 18.1% of (n=58) tumors could not be certainly assessed according to the Gross morphology. 77.5% (n=248) of tumors are primary and 22.5% (n=72) have recurrent character after prior ESD or EMR attempt. The baseline characteristics of all subjects are presented in Table 1.

Procedural characteristics, outcomes and adverse events

The mean procedure time was 82.0 minutes (±68.4). Average speed of procedure was 24.5mm²/min. The mean hospitalization stay was 4.17±1.18 days. The histopathological results of resected lesions and ESD general procedural characteristics are summarized in Table 2.

Overall, en bloc resection of rectal tumors in ESD was achieved in 92.5% (296/320) of patients. The en bloc resection rate was at a similar level in those lesions with involved anal sphincters versus tumors without involvement (93.85% vs. 92.16%; p=0.644). The R0 resection was noted in 89.4% of patients (286/320). The overall curative ESD rate was achieved in 85.94% (275/320) of patients. ESD treatment outcomes in relation to the recurrent characteristics of rectal lesions are presented in Table 3. In our study, we observed that en bloc resection was more troublesome and harder to achieve in group of larger tumors (4.58±2.67 vs. 5.64±3.19cm; p<0.001; Figure 1). The ROC curves were constructed to assign optimal cut-off values of tumor diameter associated with sustained high en bloc resection rate (AUC=0.705). The analysis showed that in patients with tumor diameter above 3.5cm (PPV=11.4%, NPV=100%) extra precautions should be implemented during the ESD procedure due to difficulties to achieve en bloc resection (Figure 2). Our study showed that the curative ESD rate was statistically higher in patients with tumors with smaller diameter (4.58±2.68 vs. 5.64±3.19cm; p=0.029; Figure 3).
In the study group, there were 11.87% (38/320) subjects with invasive cancer on final histopathology. In superficially invasive cancers the *en bloc* resection was achieved in 86.8% of cases (33/38). The R0 resection was confirmed in 84.21% (32/38) cases. Curative ESD rate in group of invasive cancer reached 52.63% (20/38). In 18 patients, in which ESD was not curative, were scheduled for surgery due to deep invasion (n=10) or positive margins (n=8). The detailed association of Paris and LST classifications in relation to cancer invasion were presented in Table 4.

In all, we observed procedure-related adverse events in 3.44% (11/320) of patients (Table 5). In 1.87% (6/320) of patients we noted early bleeding within the 24 hours after procedure, and only in 0.31% (1/320) delayed bleeding after 24 hours after ESD. All cases of bleeding responded to endoscopic treatment. Perforation occurred in 1.25% of cases (4/320), and all were closed endoscopically using mechanical therapy (clips) with full recovery.

Complications were observed more frequently in patients with large sized-tumors (6.77±3.71) compared to less diameter-tumors (4.66±2.72cm; p=0.026; Figure 4).

**Analysis of treatment predictors**

We have performed a multivariate logistic regression to identify predictors of non-curative ESD procedure (Figure 5). Our study showed that tumor diameter (OR=1.12; 95% CI: 1.01-1.23) and invasive character of lesions (OR=3.14; 95% CI: 2.15-4.57) were associated with significantly higher odds ratio of non-curative ESD procedure (Figure 5), whereas location (OR=1.04; 95% CI: 0.95-1.13), recurrent character (OR=1.07; 95% CI: 0.74-1.54), and gender (OR=1; 95% CI: 0.73-1.37) had no significant predictive value.

**Discussion**
Our study confirms the efficacy and safety of ESD procedure in treating rectal tumors (curative rate 85.94%) with low adverse effects (3.4%). Preoperative diagnosis and staging in case of rectal lesions is essential. Rectal tumors are related with diagnostic challenge, whereas complex clinical decision making is necessary to provide proper approach. Avoiding undertreatment and overtreatment, which are linked with unnecessary mortality and morbidity rates, are crucial. Recently, it has been found that 13% of the rectal tumors preoperatively staged as benign turned out to be malignant [24], however currently there are no available perfect staging modalities. In Western countries currently most lesions that have been shown not overtly cancerous on endoscopic inspection has been resected by piecemeal EMR. However, piecemeal EMR is related with an important negative impact on optimal histological assessment. The probability of “covert” cancer is associated with lesion morphology, size, and site within the colon. Regardless of morphology, all clinically benign rectal lesions > 2 cm have above 5% risk of harboring a focus of “covert” cancer [25,26]. In our study, 11.9% (38/320) of patients SMI have been confirmed in final histopathological evaluation. In those cases, the proper histopathological verification between specific type of SMI is crucial for further treatment and piecemeal EMR do not allow for accurate verification. Therefore, piecemeal EMR is inappropriate approach in at least 5% of rectal tumors >2 cm. In our opinion, in all rectal tumors >2 cm the local en bloc resection should be performed. Clinical staging of deep invasion (>T1 SM1) has been also reported accurately only in 50% in expert Western centers and local en bloc resection could have been sufficient in the other 50% of cases [26]. In our study, we have misclassified the SM infiltration of rectal lesion in 26.32% (10/38) of cases, assessing the tumor as SM1, and it turned out to be histopathological SM2/3. Our endoscopic assessment of the SM infiltration was effective in 73.68% (28/38) of patients. Only detailed pathological evaluation of the specimen can finally confirm the deep
margin and other important factors such as grading, budding and vessel invasion. The safety and feasibility of en bloc resections in the rectum, in combination with the preoperative staging limitations should lead to a shift away from piecemeal EMR to local en bloc resection of large rectal tumors. Furthermore, in a recent cost-effectiveness analysis by Bahin et al. was shown that an en bloc resections had been more financially profitable than a piecemeal EMR for rectal tumors by significantly reducing the numbers of patients demanding more radical surgical interventions [12]. It is a great place for ESD implementation as a technique that does not require an operating theater facility and enables en bloc resection of rectal lesions regardless of their size. In the study by Yamashita K et al. has been shown that the diagnostic ESD for SM2/3 rectal tumors do not affect the outcomes of subsequent surgery and long-term survival rate [27].

Another crucial advantage of local en bloc resection of possible malignant rectal tumors is improved quality of the histopathological assessment in terms of the deep margin evaluation. This observation has been confirmed in the TREND study where 3% (3/87) of patients had developed cancer recurrence after removal of a pT0 tumor in the piecemeal EMR group, versus none in the group after en bloc TEM procedure [24]. Cancer recurrence at the removal site of a benign adenoma occurs in approximately 1–2% of patients [28,29]. A possible explanation is pathological under staging with small areas of invasion being missed in the histopathological examination of the piecemeal EMR specimens. The ESD technique in our study allowed for the removal of 92.5% of the lesions en bloc and provided good quality material for histopathological examination.

Our study analyzed the outcomes of the ESD technique for resection of rectal tumors, showing that this technique is effective, safe and may be potential equivalent option for TEM/TAMIS procedures. The overall curative ESD in our study was 85.67% and there were no differences between primary and recurrent lesions (p=0.736). We observed that rectal...
curative ESD rate was statistically higher in patients with tumors with a smaller diameter (p=0.029), which was confirmed in multivariate logistic regression which indicated that only tumor size and invasiveness are significant predictors of filed en bloc resection. Even though the cutoff point indicated in the ROC analysis in our study was 3.5cm, we achieved a relatively high overall en bloc resection rate (92.5%). Our results are comparative to outcomes of ESD rectal procedures reported in meta-analysis by AP Naughton et al [30]. In our opinion, ESD in rectal tumors has important advantages over TEM/TAMIS approach. The localization of lesion or involvement of anal sphincters do not change the outcomes of endoscopic procedure. In our study, the en bloc rate of ESD among tumors involving anal sphincters was on a similar level compared to those without sphincters involvement (93.85% vs. 92.16%; p=0.644). Whereas TEM/TAMIS techniques in tumors involving anal canal or anal sphincters remains more troublesome. Moreover, ESD procedures are in general performed outside the operating room which significantly improves the cost-effectiveness outcomes of this approach. Our study confirmed that rectal lesions can be safely removed in ESD procedure, which emphasizes the validity of the local surgical or endoscopic en bloc resection of rectal tumors. ESD and TAMIS as the two main techniques recommended for local resection of rectal lesions appear to be the most attractive in future. Guidelines published in 2017 recommended that a comparison between local surgical resection and ESD is warranted to guide decision making for the appropriate treatment management of rectal tumors in Western countries [31]. Therefore, the TRISSIC study protocol have been developed to evaluate the comparison between ESD and TAMIS, instead of TEM, because TAMIS provides the benefits of advanced videoscope transanal excision at a fraction of the cost of TEM [32,33]. In TAMIS technique, there are no requirements of additional investments and the TAMIS port with its shorter shaft length allow for increased working angle and more distal resection in relation to...
the TEM[34]. Maglio et al have noted that TAMIS is associated with lower risk of sphincters injury vs. TEM.[35].

Due to the lack of results of studies directly comparing TAMIS and ESD techniques, the decision to choose one of them depends on the individual preferences of the operator. However, the primary goal is to get the highest possible rate of local en bloc resection and keep up low risk of complications. Our results showed that the ESD in the hands of a Western endoscopist trained in accordance with the ESGE curriculum meets these assumptions. Based on the results of this study, the review of current literature and our experience we recommend guidelines for the endoscopic approach for rectal lesions in Figure 6.

Potential limitations of our study should be considered. First, our study has a retrospective observational character and some of results may be susceptible to bias and a type II error. Second, our study included only patients from one endoscopic center treated by the same experienced endoscopist. Currently a prospective follow-up of included patients is ongoing to provide long-term follow-up data on the patients within our original cohort. Finally, above limitations could be circumvented with further investigations involving other endoscopists and centers, which will have a low risk of bias or a type II error.

Conclusions

In conclusions, we have observed that ESD in rectal tumors is safe approach with high curative rate, even in difficult lesions. Diagnostic ESD en bloc resection in early-stage rectal cancers may be an important alternative in improvement of the preoperative staging methods. ESD approach should have been considered for all rectal tumors, especially those lesions suspected for SMI, as it can serve as a staging method and may have been curative for adenomas and invasive cancers limited to the mucosa. In our opinion one of local resection
techniques (ESD or TEM/TAMIS) should be present in every colorectal center to facilitate rectal tumor treatment.
References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 2018, 68, 394–424.

2. Weitz, J.; Koch, M.; Debus, J.; Höhler, T.; Galle, P.R.; Büchler, M.W. Colorectal cancer. In Proceedings of the Lancet; Lancet, 2005; Vol. 365, pp. 153–165.

3. Jankowski, M.; Bała, D.; Las-Jankowska, M.; Wysocki, W.M.; Nowikiewicz, T.; Zegarski, W. Overall treatment outcome – analysis of long-term results of rectal cancer treatment on the basis of a new parameter. Arch. Med. Sci. 2020, 16, 825–833.

4. Näsvall, P.; Dahlstrand, U.; Löwenmark, T.; Rutegård, J.; Gunnarsson, U.; Strigård, K. Quality of life in patients with a permanent stoma after rectal cancer surgery. Qual. Life Res. 2017, 26, 55–64.

5. Pimentel-Nunes, P.; Dinis-Ribeiro, M.; Ponchon, T.; Repici, A.; Vieth, M.; De Ceglie, A.; Amato, A.; Berr, F.; Bhandari, P.; Bialek, A.; et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015, 47, 829–854.

6. Nam, M.J.; Sohn, D.K.; Hong, C.W.; Han, K.S.; Kim, B.C.; Chang, H.J.; Park, S.C.; Oh, J.H. Cost comparison between endoscopic submucosal dissection and transanal endoscopic microsurgery for the treatment of rectal tumors. Ann. Surg. Treat. Res. 2015, 89, 202–207.

7. Ahlenstiel, G.; Hourigan, L.F.; Brown, G.; Zanati, S.; Williams, S.J.; Singh, R.; Moss, A.; Sonson, R.; Bourke, M.J. Actual endoscopic versus predicted surgical mortality for treatment of advanced mucosal neoplasia of the colon. Gastrointest. Endosc. 2014, 80, 668–676.

8. Tanaka, S.; Kashida, H.; Saito, Y.; Yahagi, N.; Yamano, H.; Saito, S.; Hisabe, T.; Yao,
T.; Watanabe, M.; Yoshida, M.; et al. Japan Gastroenterological Endoscopy Society guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. *Dig. Endosc.* 2020, 32, 219–239.

9. Draganov, P. V.; Wang, A.Y.; Othman, M.O.; Fukami, N. AGA Institute Clinical Practice Update: Endoscopic Submucosal Dissection in the United States. *Clin. Gastroenterol. Hepatol.* 2019, 17, 16-25.e1.

10. Akintoye, E.; Kumar, N.; Aihara, H.; Nas, H.; Thompson, C. Colorectal endoscopic submucosal dissection: a systematic review and meta-analysis. *Endosc. Int. Open* 2016, 04, E1030–E1044.

11. Burgess, N.G.; Bourke, M.J. Endoscopic resection of colorectal lesions: The narrowing divide between East and West. *Dig. Endosc.* 2016, 28, 296–305.

12. Bahin, F.F.; Heitman, S.J.; Rasouli, K.N.; Mahajan, H.; McLeod, D.; Lee, E.Y.T.; Williams, S.J.; Bourke, M.J. Wide-field endoscopic mucosal resection versus endoscopic submucosal dissection for laterally spreading colorectal lesions: A cost-effectiveness analysis. *Gut* 2018, 67, 1965–1973.

13. Holmes, I.; Friedland, S. Endoscopic mucosal resection versus endoscopic submucosal dissection for large polyps: A western colonoscopist’s view. *Clin. Endosc.* 2016, 49, 454–456.

14. Fujishiro, M.; Yahagi, N.; Kakushima, N.; Kodashima, S.; Muraki, Y.; Ono, S.; Yamamichi, N.; Tateishi, A.; Oka, M.; Ogura, K.; et al. Outcomes of Endoscopic Submucosal Dissection for Colorectal Epithelial Neoplasms in 200 Consecutive Cases. *Clin. Gastroenterol. Hepatol.* 2007, 5, 678–683.

15. McCarty, T.R.; Bazarbashi, A.N.; Hathorn, K.E.; Thompson, C.C.; Aihara, H. Endoscopic submucosal dissection (ESD) versus transanal endoscopic microsurgery (TEM) for treatment of rectal tumors: a comparative systematic review and meta-
analysis. *Surg. Endosc.* **2020**, *34*, 1688–1695.

16. Sagae, V.M.T.; Ribeiro, I.B.; de Moura, D.T.H.; Brunaldi, V.O.; Logiudice, F.P.; Funari, M.P.; Baba, E.R.; Bernardo, W.M.; de Moura, E.G.H. Endoscopic submucosal dissection versus transanal endoscopic surgery for the treatment of early rectal tumor: a systematic review and meta-analysis. *Surg. Endosc.* 2020, *34*, 1025–1034.

17. Spychalski, M.; Zelga, P.; Dziki, A. Key factors in achieving successful endoscopic dissection of rectal tumors: Early results of 33 consecutive rectal endoscopic submucosal dissections in polish academic center. *Surg. Laparosc. Endosc.* *Percutaneous Tech.* **2015**, *25*, 173–177.

18. Spychalski, M.; Dziki, A. Safe and efficient colorectal endoscopic submucosal dissection in European settings: Is successful implementation of the procedure possible? *Dig. Endosc.* **2015**, *27*, 368–373.

19. Spychalski, M.; Skulimowski, A.; Dziki, A.; Saito, Y. Colorectal endoscopic submucosal dissection (ESD) in the West—when can satisfactory results be obtained? A single-operator learning curve analysis. *Scand. J. Gastroenterol.* **2017**, *52*, 1442–1452.

20. Spychalski, M.; Skulimowski, A.; Nishimura, M.; Dziki, A. Comparison of Endoscopic Submucosal Dissection for Primary and Recurrent Colorectal Lesions: A Single-Center European Study. *J. Laparoendosc. Adv. Surg. Tech.* **2019**, *29*, 366–373.

21. Rubio, C.A.; Nesi, G.; Messerini, L.; Zampi, G.C.; Mandai, K.; Itabashi, M.; Takubo, K. The Vienna classification applied to colorectal adenomas. *J. Gastroenterol.* *Hepatol.* **2006**, *21*, 1697–1703.

22. Nagtegaal, I.D.; Odze, R.D.; Klimstra, D.; Paradis, V.; Rugge, M.; Schirmacher, P.; Washington, K.M.; Carneiro, F.; Cree, I.A. The 2019 WHO classification of tumours of the digestive system. *Histopathology* **2020**, *76*, 182–188.

23. Kothari, S.T.; Huang, R.J.; Shaukat, A.; Agrawal, D.; Buxbaum, J.L.; Abbas Fehmi,
S.M.; Fishman, D.S.; Gurudu, S.R.; Khashab, M.A.; Jamil, L.H.; et al. ASGE review of adverse events in colonoscopy. Gastrointest. Endosc. 2019, 90, 863-876.e33.

24. Barendse, R.M.; Musters, G.D.; de Graaf, E.J.R.; van den Broek, F.J.C.; Consten, E.C.J.; Doornebosch, P.G.; Hardwick, J.C.; de Hingh, I.H.J.T.; Hoff, C.; Jansen, J.M.; et al. Randomised controlled trial of transanal endoscopic microsurgery versus endoscopic mucosal resection for large rectal adenomas (TREND Study). Gut 2018, 67, 837–846.

25. Burgess, N.G.; Hourigan, L.F.; Zanati, S.A.; Brown, G.J.; Singh, R.; Williams, S.J.; Raftopoulos, S.C.; Ormonde, D.; Moss, A.; Byth, K.; et al. Risk Stratification for Covert Invasive Cancer Among Patients Referred for Colonic Endoscopic Mucosal Resection: A Large Multicenter Cohort. Gastroenterology 2017, 153, 732-742.e1.

26. Moss, A.; Bourke, M.J.; Williams, S.J.; Hourigan, L.F.; Brown, G.; Tam, W.; Singh, R.; Zanati, S.; Chen, R.Y.; Byth, K. Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia. Gastroenterology 2011, 140, 1909–1918.

27. Yamashita, K.; Oka, S.; Tanaka, S.; Nagata, S.; Hiraga, Y.; Kuwai, T.; Furudoi, A.; Tamura, T.; Kunihiro, M.; Okanobu, H.; et al. Preceding endoscopic submucosal dissection for T1 colorectal carcinoma does not affect the prognosis of patients who underwent additional surgery: a large multicenter propensity score-matched analysis. J. Gastroenterol. 2019, 54, 897–906.

28. Saito, Y.; Fukuzawa, M.; Matsuda, T.; Fukunaga, S.; Sakamoto, T.; Uraoka, T.; Nakajima, T.; Ikehara, H.; Fu, K.-I.; Itoi, T.; et al. Clinical outcome of endoscopic submucosal dissection versus endoscopic mucosal resection of large colorectal tumors as determined by curative resection. Surg. Endosc. 2010, 24, 343–352.

29. Van Den Broek, F.J.C.; De Graaf, E.J.R.; Dijkgraaf, M.G.W.; Reitsma, J.B.;
30. Naughton, A.P.; Ryan, É.J.; Bardon, C.T.; Boland, M.R.; Aherne, T.M.; Kelly, M.E.; Whelan, M.; Neary, P.C.; McNamara, D.; O’Riordan, J.M.; et al. Endoscopic management versus transanal surgery for early primary or early locally recurrent rectal neoplasms—a systematic review and meta-analysis. *Int. J. Colorectal Dis.* 2020, 35, 2347–2359.

31. Ferlitsch, M.; Moss, A.; Hassan, C.; Bhandari, P.; Dumonceau, J.M.; Paspatis, G.; Jover, R.; Langner, C.; Bronzwaer, M.; Natalkili, K.; et al. Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Endoscopy* 2017, 49, 270–297.

32. Dekkers, N.; Boonstra, J.J.; Moons, L.M.G.; Hompes, R.; Bastiaansen, B.A.; Tuynman, J.B.; Koch, A.D.; Weusten, B.L.A.M.; Pronk, A.; Neijenhuis, P.A.; et al. Transanal minimally invasive surgery (TAMIS) versus endoscopic submucosal dissection (ESD) for resection of non-pedunculated rectal lesions (TRIASSIC study): Study protocol of a European multicenter randomised controlled trial. *BMC Gastroenterol.* 2020, 20, 1–9.

33. Atallah, S.; Albert, M.; Larach, S. Transanal minimally invasive surgery: A giant leap forward. *Surg. Endosc.* 2010, 24, 2200–2205.

34. Martin-Perez, B.; Andrade-Ribeiro, G.D.; Hunter, L.; Atallah, S. A systematic review of transanal minimally invasive surgery (TAMIS) from 2010 to 2013. *Tech. Coloproctol.* 2014, 18, 775–788.

35. Maglio, R.; Marco Muzi, G.; Meucci Massimo, M.; Masoni, L. Transanal minimally invasive surgery (Tamis): New treatment for early rectal cancer and large rectal polyps—experience of an Italian center. *Am. Surg.* 2015, 81, 273–277.
Table and figure legends

Table 1. Baseline characteristics of the study group

Table 2. Endoscopic submucosal dissection procedural characteristics.

Table 3. Endoscopic submucosal dissection treatment outcomes in relation to the recurrent characteristics of rectal lesions

Table 4. The detailed association of Paris and LST classifications in relation to cancer invasion.

Table 5. Adverse effects of ESD procedure in rectal tumors

Figure 1. The relationship of tumor diameter and en bloc resection in rectal tumors

(4.58±2.67 vs. 6.66±3.37; p<0.001)

Figure 2. Receiver operating characteristic curve for tumor diameter and the en bloc resection rate with indicated cutoff point for 3.5 cm (100% sensitivity, 34.1% specificity).

Figure 3. The relationship between the curative ESD rate of endoscopic submucosal resection of rectal tumors and diameter of lesion (4.58±2.68 vs. 5.64±3.19; p=0.029).

Figure 4. The relationship between tumor diameter and occurrence of severe adverse events

(6.77±3.71cm vs. 4.66±2.72; p=0.026).

Figure 5. Forrest plot presenting the odds ratio for achieving a curative ESD procedure.

Figure 6. The proposed guidelines for the endoscopic approach for rectal lesions.
| Age (years) | 64.69 ± 11.06 |
|------------|---------------|
| **Sex**    |               |
| Female     | 149 (46.56%)  |
| Male       | 171 (53.44%)  |
| **Primary tumor** | 248 (77.5%) |
| **Recurrence after EMR** | 72 (22.5%) |
| **Gross morphology** |               |
| LST-G      | 229 (71.56%)  |
| LST-NG     | 33 (10.31%)   |
| n/a        | 58 (18.12%)   |
| **Paris Classification** |               |
| IIa        | 144 (45%)     |
| IIa+c      | 52 (16.3%)    |
| IIa+Is     | 74 (23.1%)    |
| Is         | 48 (15%)      |
| Is +IIa    | 2 (0.6%)      |

**Table 1.** Baseline characteristics of the study group (n/a – not assessed; EMR – endoscopic mucosal resection)
| Histopathological evaluation | Adenoma minor dysplasia | 91 (28.44%) |
|-------------------------------|-------------------------|-------------|
| Adenoma major dysplasia       | 144 (45%)               |             |
| Invasive adenocarcinoma       | 38 (11.87%)             |             |
| Carcinoma in situ            | 44 (13.75)              |             |
| Sessile serrated adenoma      | 3 (0.94%)               |             |

| Tumor size [cm] | 4.74 ± 2.78             |
| Mean procedure time [min] | 82.89 ± 68.4             |
| Average speed of tumor dissection [mm²/min] | 24.5 ± 14.59 |
| Length from anal verge [cm] | 4.51 ± 3.5             |

**Table 2.** Endoscopic submucosal dissection procedural characteristics.
|                       | Primary tumour  | Recurrent tumour | p-value |
|-----------------------|----------------|-----------------|---------|
| **En bloc**           | 233 (93.95%)   | 63 (87.5%)      | p=0.067 |
| **R0**                | 225 (90.73%)   | 61 (84.72%)     | p=0.146 |
| **Curative ESD rate** | 214 (86.29%)   | 61 (84.72%)     | p=0.736 |

**Table 3.** Endoscopic submucosal dissection treatment outcomes in relation to the recurrent characteristics of rectal lesions
| Paris classification | Invasive cancer | No invasive lesion | p       |
|----------------------|----------------|-------------------|---------|
| IIa                  | 9 (6.25%)      | 135 (93.75%)      | p=0.002 |
| Is                   | 11 (22.92%)    | 37 (77.08%)       |         |
| IIa+C                | 12 (23.08%)    | 40 (76.92%)       |         |
| IIa+Is               | 6 (8.11%)      | 68 (91.89%)       |         |
| Is +IIA              | 0              | 2 (100%)          |         |
| LST classification  |                |                   |         |
| LST-NG               | 10 (30.3%)     | 23 (69.7%)        | p<0.001 |
| LST-G                | 20 (8.73%)     | 209 (91.27%)      |         |

**Table 4.** The detailed association of Paris and LST classifications in relation to cancer invasion.
| Adverse Effect                                      | Count (Percentage) |
|----------------------------------------------------|--------------------|
| Early bleeding (<24 hours after ESD procedure)     | n=6 (1.87%)        |
| Delayed bleeding (>24 hours after ESD)             | n=1 (0.31%)        |
| Perforation                                        | n=4 (1.25%)        |

*Table 5. Adverse effects of ESD procedure in rectal tumors*
Figure 1. The relationship of tumor diameter and en bloc resection in rectal tumors (4.58±2.67 vs. 6.66±3.37; p<0.001)
Figure 2. Receiver operating characteristic curve for tumor diameter and the en bloc resection rate with indicated cutoff point for 3.5 cm (100% sensitivity, 34.1% specificity).
Figure 3. The relationship between the curative ESD rate of endoscopic submucosal resection of rectal tumors and diameter of lesion (4.58±2.68 vs. 5.64±3.19; p=0.029).
Figure 4. The relationship between tumor diameter and occurrence of severe adverse events (6.77±3.71cm vs. 4.66±2.72; p=0.026).
Figure 5. Forrest plot presenting the odds ratio for achieving a curative ESD procedure.
Rectal tumor/polyp: *en block* resection mandatory in case of any risk of malignancy

| SIZE  | Location                  | Morphology                                                                 |
|-------|---------------------------|-----------------------------------------------------------------------------|
| <2    | Easy: middle rectum       | Benign                                                                      |
| 2-5   | Difficult: close to anal verge, proximal rectum | Advanced: depression (Paris II A+C), large sessile lesion, abnormal vascular or surface pattern (NICE III/Kudo V) |
| >5 cm |                                                          |                                                                             |

Send to reference centre where ESD or TEM/TAMIS is possible

ESD – preferably in difficult localization, primary lesions, lesions with diameter over 5 cm

TEM/TAMIS – preferably in recurrent lesions, when mucosal closure is needed (anticoagulants)

Figure 6. The proposed guidelines for the endoscopic approach for rectal lesions.